Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis [Corrigendum]

This article refers to:

Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis

Kameoka Y, Kishi F, Koura M, et al. Drug Des Devel Ther. 2019;13:555–568.

The authors have advised that there was an error in the text.

Page 561, beginning at the left-hand bottom of the page, “The number of peripheral blood lymphocytes and granulocytes did not change in the aVAP2-administered mice: WBCs: 4.42 (1.36–7.57)×10⁹ cells/L vs 3.14 (1.48–15.7)×10⁹ cells/L (Figure S3A). The number of granulocytes decreased: 0.15 (0.05–1.04)×10⁹ cells/L vs 0.22 (0.04–0.69)×10⁹ cells/L (Figure S3B).” should instead read “The number of peripheral blood lymphocytes and granulocytes did not change in the aVAP2-administered mice: WBCs: 2.11 (1.36–2.44)×10⁹ cells/L vs 3.14 (1.48–15.7)×10⁹ cells/L (Figure S3A). The number of granulocytes decreased: 0.055 (0.03–0.08)×10⁹ cells/L vs 0.22 (0.04–0.69)×10⁹ cells/L (Figure S3B).”